Biology:GamEvac-Combi
| Vaccine description | |
|---|---|
| Target disease | Ebola |
| Type | heterologous |
| Legal status | |
| Legal status |
|
GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine. There is also a version called GamEvac which is a homologous Ad5-vectored vaccine.[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology. (As of 2015) the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.[2]
Description
The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.[3] The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.[4]
History
GamEvac-Combi was licensed by the Ministry of Health of the Russian Federation for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.[2]
See also
- Gam-COVID-Vac
References
- ↑ "Virus-Vectored Ebola Vaccines". Acta Naturae 9 (3): 4–11. 2017. doi:10.32607/20758251-2017-9-3-4-11. PMID 29104771.
- ↑ 2.0 2.1 "Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations". World Health Organization. https://www.who.int/immunization/sage/meetings/2018/october/2_Ebola_SAGE2018Oct_BgDoc_20180919.pdf.
- ↑ "Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia". Human Vaccines & Immunotherapeutics 13 (3): 613–620. March 2017. doi:10.1080/21645515.2016.1238535. PMID 28152326.
- ↑ "Ebola virus disease". Lancet 393 (10174): 936–948. March 2019. doi:10.1016/s0140-6736(18)33132-5. PMID 30777297.
 |  |
